(Reuters) -Pharmacy middlemen are working on a proposal to change some of their business practices to avoid new regulation from the Trump administration, Bloomberg News reported on Wednesday, citing people familiar with the discussions.

The Pharmaceutical Care Management Association, a key lobbying group for pharmacy middlemen, is drafting recommendations to present to the Centers for Medicare and Medicaid Services, Bloomberg reported, citing a reviewed document.

Proposals under discussion include measures such as ensuring patients do not pay more than the cash price charged to uninsured customers, increasing the use of lower-cost alternatives to expensive biologic drugs and increasing reimbursement rates for rural and independent pharmacies.